Michael Goettler, Viatris CEO

First in­ter­change­able biosim­i­lar launch­es in the US with a tiny dis­count on list price

Vi­a­tris (for­mer­ly known as My­lan and Pfiz­er’s Up­john) on Tues­day opened up on the pric­ing of its in­ter­change­able biosim­i­lar for the in­sulin Lan­tus, say­ing the list price would be set at about $400 for a pack­age of five 3 mL pens, which is about $20 cheap­er than the list price for the brand­ed ver­sion.

The tiny dis­count on Sem­glee’s list price (and the net price dis­count is ex­pect­ed to be less) of­fers the first look at how in­ter­change­able biosim­i­lars in the US, mean­ing they can be sub­sti­tut­ed for the orig­i­nal in­sulins with­out a doc­tor’s in­put, might be con­sid­ered clos­er cousins to their brand­ed coun­ter­parts when it comes to price than oth­er un­brand­ed biosim­i­lars.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA